Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
News Jun 19, 2014
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 1.0 m to Evotec.
The milestone was for the transition of a back-up compound from a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE